Close Menu

Regulus

The funding coincides with publication of reports from the Extracellular RNA Consortium outlining growth and challenges in exosomal RNA-based diagnostics.

The company provided updates for its hepatitis C and Alport syndrome candidates, which are both set to enter Phase II testing this year.

The data also point to viral load reductions regardless of disease genotype, extent of patient liver fibrosis, or failure with other treatments.

Regulus said it was able to develop its miRNA extraction and profiling technology to meet the quality specifications set out by its partner.

The delivery approach has gained traction in recent years and is being explored by a number of RNA drug firms.

The data show that RG-012 can enhance the effect of Sanofi's kidney protectant ramipril and suggest the microRNA drug might have use in other chronic kidney diseases.

NEW YORK (GenomeWeb) — October was a turbulent month on Wall Street for several key RNAi/microRNA players, with two companies — Regulus Therapeutics and Alnylam Pharmaceuticals — seeing major gains on encouraging clinical data and two others — Arrowhead Research and Tekmira Pharmaceuticals — taki

NEW YORK (GenomeWeb) — Buoyed by positive Phase I data on its microRNA-targeting hepatitis C drug RG-101, Regulus Therapeutics is aiming to begin Phase II testing of the dr

NEW YORK (GenomeWeb) — Regulus Therapeutics announced this week that it has closed its previously announced public stock offering, raising $103.5 million through the transaction.

NEW YORK (GenomeWeb) — Regulus Therapeutics this week announced that it had priced its previously announced public offering of roughly 5.3 million shares of its common stock at $17 apiece, valuing the transaction at about $90 million.

Pages

Forensic genetic firm Verogen has bought the genetic genealogy site GEDmatch.

Researchers have 3D-printed plastic bunnies that encase the information needed to make more such bunnies in DNA, according to Discover magazine.

Dan Rather, the former CBS Evening News anchor and executive producer of a new documentary, writes at the Guardian that everyone needs to know about CRISPR.

In PNAS this week: analysis of FOXA1 upregulation in ER-positive breast cancer, gene editing to correct recessive dystrophic epidermolysis bullosa, and more.